Scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability. By inserting a gene for a bispecific T cell engager (BiTE) within the EnAdenotucirev genome, Seymore et al were able to drive direct oncolysis and T cell mediated killing of EpCAM expressing tumour cells with high efficiency.
Read the article: http://embomolmed.embopress.org/content/embomm/early/2017/06/20/emmm.201707567.full.pdf
